Landgren Maria

💡 Mild ulcerative colitis and Crohn's disease are common and possibly predictable New findings from PREDICT - Center for Molecular Prediction of Inflammatory Bowel Disease found new clues in patients with the Danish healthcare system ✅ Based on treatment history, the prevalence of mild-onset ulcerative colitis and Crohn's disease was 63% and 25% ✅ 20 years after diagnosis: 🔸One out of three patients with mild-onset UC 🔸Two out of three patients with mild-onset CD 👉 progressed to moderate-severe disease 👉 a large proportion of patients with mild ulcerative colitis maintained a mild disease course ✅ Young age at diagnosis (< 18 years) was associated with a higher probability of progression ✅ The probability of progression to moderate-severe disease decreased with the duration of mild disease 👉 Identifying patients with mild IBD is crucial to prevent overtreatment, and nutritional therapies may play a role in helping patients with IBD stay long-term in mild disease 📸 Clinical Gastroenterology & Hepatology

11

1 kommentar

Intriguing Role of GLP-I: How It Impacts Insulin and the Brain Dr. Christoffer Clemmensen talks about GLP-I's presence in the pancreas, nervous system, and brain. Explore its role in insulin secretion and brain function, as well as how it crosses the blood-brain barrier. Discover the fascinating connections between GLP-I, food uptake, and nutrient acquisition. Clip from this podcast conversation: https://lnkd.in/gUQiug_G #Metabolism #Diet #Nutrition #GLP1 #Ozempic #Biology #Science #Podcast #WeightLoss

2

Bladder Cancer Prevention: key policy recommendations 1️⃣ Improve legislation in the field of occupational cancer to recognise the link between certain chemicals and bladder cancer explicitly. Include bladder cancer in the list of occupational cancers in future revisions of the EU Carcinogens Directive. 2️⃣ Ensure the implementation of minimum standards on tobacco use. The introduction of pictorial warnings on bladder cancer in the EU Tobacco Directive should complement these actions. Explore detailed policy recommendations in our White Paper 👉 <https://ow.ly/UqAA50QiCLr> #bladdercancer #bladdercancersupport #whitepaperbladdercancer #fightbladdercancer #bladdercanceradvocacy #bladdercancersupport #bladdercancercare #bladdercanceraware #bladdercancerpolicy #bladdercancereurope #ESMO24

7

Bladder Cancer Prevention: key policy recommendations 1️⃣ Improve legislation in the field of occupational cancer to recognise the link between certain chemicals and bladder cancer explicitly. Include bladder cancer in the list of occupational cancers in future revisions of the EU Carcinogens Directive. 2️⃣ Ensure the implementation of minimum standards on tobacco use. The introduction of pictorial warnings on bladder cancer in the EU Tobacco Directive should complement these actions. Explore detailed policy recommendations in our White Paper 👉 <https://ow.ly/UqAA50QiCLr> #bladdercancer #bladdercancersupport #whitepaperbladdercancer #fightbladdercancer #bladdercanceradvocacy #bladdercancersupport #bladdercancercare #bladdercanceraware #bladdercancerpolicy #bladdercancereurope #ESMO24

17

Bone Marrow Cancer Treatment Under Review: Medicinrådet Reevaluates Lenalidomide Recommendation After Disappointing Real-World Results The Danish Medicines Council (Medicinrådet) is reassessing its recommendation for lenalidomide (Revlimid by Bristol Myers Squibb) as a maintenance therapy for bone marrow cancer following a Danish real-world study that revealed significantly lower effectiveness than anticipated. The study found that lenalidomide did not improve overall or progression-free survival and led to a high rate of treatment discontinuation due to adverse side effects. This unexpected outcome contrasts with the positive results from earlier clinical trials and has prompted Medicinrådet to reconsider the drug's viability as a long-term therapy. A final decision, balancing patient outcomes and healthcare sustainability, is expected later this year. For more details please click the link! https://lnkd.in/dcw2Zs4e #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

1

🇸🇪 Medaffcon's operations in Sweden are well-established and growing, offering pharmaceutical companies RWE studies and Market Access services delivered by Data Scientists, Market Access experts, and RWE specialists working together. A key therapeutic area is oncology. Lisse-Lotte Hermansson, Medaffcon's Country Director, M.Sc (Econ.) & M.Sc (Health Econ) in Sweden, has a clear vision of what Medaffcon can offer pharmaceutical companies and other clients in Sweden, Denmark, and across the Nordics. She emphasizes that the results of data analysis move beyond borders: Real-world data (RWD) from Sweden and Finland serves clients worldwide. 💡 Oncology is currently Medaffcon's most important therapeutic area, with several #RWE (real-world evidence) projects underway focusing on eg lung cancer. Other important areas include large chronic illnesses such as asthma and autoimmune diseases. In addition to Lisse-Lotte Hermansson, Scientific Advisor Johan Rehnberg is physically based in Sweden, but the team works in a hybrid model. Medaffcon's top experts in #Finland also contribute to projects in #Sweden. ➡️ Read the whole article here ➡️ https://lnkd.in/dbRzWUjz #realworldevidence #RWD

26

CMTA-STAR Alliance Partner NMD Pharma A/S has announced the publication of foundational findings in the Annals of Clinical and Translational Neurology. The study highlights neuromuscular junction (NMJ) dysfunction as a characteristic in Charcot-Marie-Tooth disease (CMT) types 1 and 2, identifying its impact on muscle function and disease severity. This research laid the groundwork for NMD Pharma’s SYNAPSE-CMT Phase II clinical trial, which is now actively recruiting participants. Learn more: https://lnkd.in/eeKh74kw #CMTResearch #CMTASTAR #CharcotMarieTooth #CMTDisease #LetsBeatCMT #CMTAFamily

6

Did you know that not only do Lyme disease patients deal with physical symptoms, but they also face a lot of uncertainty and stress that can lead to PTSD? A new study surveyed 231 adults with persistent Lyme disease through social media platforms like Facebook, Twitter, and Instagram. It revealed a strong link between uncertainty in illness and PTSD symptoms in these patients. High levels of stress, anxiety, and depression were reported, often stemming from difficult interactions with medical providers and social challenges. While more research is needed, it's important to be aware of mental health symptoms in chronic illnesses, including Lyme disease, to better support those who are suffering. Check out the science from Pace University: https://lnkd.in/eFcV6s2q #projectlyme #lyme #tickbornediseases #lymediseaseawareness #health #mentalhealth #tickbite #medicine #chroniclyme #cognitive #brainfog #science #research #lymediseaseawarenessmonth #mentalhealthawarenessmonth

16

1 kommentar

Outcomes of 10 years of PSA screening for Prostate Cancer in Norwegian men with Lynch syndrome https://lnkd.in/dcFuQtVX This prospective observational study investigated #ProstateCancer (PCa) incidence and characteristics in 225 male carriers of pathogenic germline variants in mismatch repair (MMR) genes, specifically focusing on the MSH2 and MSH6 genes, who underwent annual PSA screening in Norway. Of the participants, 22 (9.8%) developed PCa, with MSH2 and MSH6 carriers showing the highest incidence rates (14.5% and 13.1%, respectively). Half of the tumors had a Gleason score ≥4+3, indicating aggressive disease, and a substantial proportion had advanced pathological stages. The standardized incidence ratio (SIR) for all MMR carriers was 9.54, with even higher SIRs for MSH2 (13.0) and MSH6 (13.74) carriers, suggesting a significantly increased PCa risk. These findings support the continuation of PSA screening for MSH2 and MSH6 carriers, though further studies are needed to refine screening recommendations for other MMR gene carriers.  Manuela Zucknick Astrid Stormorken Karol Axcrona  Lovise Mæhle Aurelius Omlin Silke Gillessen Bárbara Melão Dra. María Natalia Gandur Quiroga

1

A new study from Karolinska Institutet shows intrauterine mepivacaine significantly reduces pain during IUD placement in nulliparous women. This could help address pain-related barriers to IUD adoption. #ReproductiveHealth #LARC Read more: https://lnkd.in/ezi-tKA3

1

🌟 Medaffcon at #ISPOREurope: Unlocking Insights in Lung Cancer 🌟 Today, Medaffcon is proud to present two impactful posters on lung cancer at ISPOR Europe: 📌 Morning: End-of-life treatment of lung cancer patients in Finland—providing valuable insights into care pathways during critical stages. 📌 Afternoon: Effect of smoking status in lung cancer—examining how smoking history influences healthcare resource use. Both studies leverage Finland’s rich, granular clinical data from a Finnish data lake, enabling advanced analyses that support health technology assessments (HTA) and beyond. We’re eager to discuss how our expertise in real-world data can support your projects. Reach out to us to explore collaboration opportunities and learn more about our innovative work! #ISPOREurope #Medaffcon #RWE #HTA

29

2 kommentarer

Novo Nordisk announced the presentation of 21 abstracts (7 oral and 14 short oral presentations) at the upcoming 60th Annual Meeting of the European Association for the Study of Diabetes (EASD), which will take place from 9 to 13 September 2024 in Madrid, Spain. Read More: https://lnkd.in/geP9xPWs “Cardiometabolic conditions like diabetes, obesity, cardiovascular and kidney disease, all result from closely interlinked underlying risk factors and are among the most significant health challenges society faces today. Tailored treatment options that aim to holistically address these conditions are therefore needed,” said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. “At EASD this year, we are showcasing new data from across our diabetes, obesity, cardiovascular and renal pipeline and portfolio, where we continue to push boundaries with the goal of advancing treatments in order to help more patients.” #mededgema #NovoNordisk #EASD2024 #DiabetesResearch #Type2Diabetes #CardiometabolicHealth #ObesityManagement #KidneyHealth #PharmaInnovation #Endocrinology #SemaglutideResearch

7

Reducing the use of broad-spectrum antibiotics reduces the antibiotic load on the population and thereby reduces future resistance. But it’s not that simple for individuals. Hear from Dr. Gorm Lisby, Chief Consultant, Amager and Hvidovre Hospital, Department of Clinical Microbiology, how rapid diagnostic technologies help at both the individual and societal levels: https://lnkd.in/dhRemqiE #AMR #AntimicrobialResistance #WAAW #sepsis

32

📊 RWE Study Shows: New #Diabetes Medications Were Actively Adopted Between 2012–2019 – The Results Are Promising The adoption of new diabetes medications in Finland was active between 2012 and 2019, according to an RWE (Real World Evidence) study published in May 2024. The study was conducted by Medaffcon in collaboration with the pharmaceutical company Sanofi. According to Medaffcon's Sr. Scientific Advisor, RWE Lead, PhD Mariann Lassenius, the study found that average long-term blood glucose levels mostly remained within target ranges despite the aging population, although some people with diabetes did not reach the reference values. 📊 The study aimed to describe the clinical characteristics and medication purchases of adults receiving insulin therapy in Finland at baseline (January 1, 2012, or the first insulin purchase) and by December 31, 2019. Additionally, it outlined the patterns of basal insulin (BI) usage and associated changes in hemoglobin A1c (HbA1c) levels. “The strength of this RWE study lies in its nationwide coverage and its focus on type 1 and type 2 diabetes patients treated exclusively with insulin,” described Medaffcon's Sr. Scientific Advisor, RWE Lead, PhD Mariann Lassenius. ❓ Why do the results help demonstrate the need for new diabetes medications?❓ ➡ Read the whole arcticle here: ➡ https://lnkd.in/dYVSriVj #RWE #Studies #Pharmaceutical #Medications #healthresourch

23

👶🏽👶🏼👶🏻Outcomes of children born to women with rheumatic diseases. Presented at #EULAR2024 by Ass. Prof. Laura Andreoli from #CeViG. In this session "Family Planning, Fertility and Pregnancy in RMDs". Laura presented the focus on the frequently asked questions by patients, which can be basically summarized into "Will I have a healthy child?"🍀 The concerns around children's outcomes are one of the reasons why women living with RMDs have fewer children than originally desired. Fears are both related to short- and long-term outcomes. ➖They are afraid of passing on their disease to the offspring and harming their babies through medications taken during pregnancy and/or disease factors such as autoantibodies. ➖They wonder whether children should receive vaccinations as per schedule or if they should undergo special exams. ➖Women wonder whether their children will be more prone to develop neurodevelopmental disorders such autism-spectrum-disorders. Answers to these questions are not always clear-cut and sometimes are based on little and low-quality scientific evidence. Yesterday Laura presented the uncertainties around these topics and provide hints at the future research agenda🍀 Laura Andreoli is Associate Professor of Rheumatology, University of Brescia, Italy. She is Associate Professor at The Center for Viden om Gigt (CeViG) / Danish Centre for Expertise in Rheumatology & Dansk Gigthospital (The Danish Hospital for Rheumatic Diseases), and Adjunct Professor at the Department of Regional Health Research, University of Southern Denmark, Odense #EULAR2024 #Rheumatology #Research #RMD #FamilyPlanning

27

Liselotte Hyveled, Chief Patient Officer, Board member, Novo Nordisk [CPH: NOVO-B] Contributed an article "Strengthening Patient Centricity in Drug Development: The New Evolution in Pharma" “Strengthening patient centricity in drug development is not just an evolution but a revolution in the pharmaceutical industry. By placing patients at the heart of the development process, companies are not only improving treatment outcomes but also enhancing the overall patient experience,” says Liselotte Hyveled. The article will also be featured in the forthcoming special print edition of Pharma Manufacturing 2025. Read More: https://lnkd.in/gwcGbfxv #PatientCentricity #PharmaceuticalInnovation #DrugDevelopment #PatientEngagement #HealthcareTransformation #ClinicalTrials #PatientAdvocacy #TreatmentOutcomes #PharmaRevolution #QualityOfLife

70

2 kommentarer